title: Qishen Yiqi Drop Pill improves cardiac function after myocardial ischemia.
abstract: Myocardial ischemia (MI) is one of the leading causes of death, while Qishen Yiqi Drop Pill (QYDP) is a representative traditional Chinese medicine to treat this disease. Unveiling the pharmacological mechanism of QYDP will provide a great opportunity to promote the development of novel drugs to treat MI. 64 male Sprague-Dawley (SD) rats were divided into four groups: MI model group, sham operation group, QYDP treatment group and Fosinopril treatment group. Echocardiography results showed that QYDP exhibited significantly larger LV end-diastolic dimension (LVEDd) and LV end-systolic dimension (LVEDs), compared with the MI model group, indicating the improved cardiac function by QYDP. (1)H-NMR based metabonomics further identify 9 significantly changed metabolites in the QYDP treatment group, and the QYDP-related proteins based on the protein-metabolite interaction networks and the corresponding pathways were explored, involving the pyruvate metabolism pathway, the retinol metabolism pathway, the tyrosine metabolism pathway and the purine metabolism pathway, suggesting that QYDP was closely associated with blood circulation. ELISA tests were further employed to identify NO synthase (iNOS) and cathepsin K (CTSK) in the networks. For the first time, our work combined experimental and computational methods to study the mechanism of the formula of traditional Chinese medicine.
authors.affiliation: Beijing University of Chinese Medicine, Beijing 100029, China.|Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
authors.forename: Chen
authors.initials: C
authors.lastname: JianXin
authors.affiliation: School of Electronic and Information Engineering, South China University of Technology, Guangzhou 510641, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Xue
authors.affiliation: Department of Chemistry, Capital Normal University, Beijing 100048, China.
authors.forename: Li
authors.initials: L
authors.lastname: ZhongFeng
authors.affiliation: Beijing University of Chinese Medicine, Beijing 100029, China.
authors.forename: Gao
authors.initials: G
authors.lastname: Kuo
authors.affiliation: School of Electronic and Information Engineering, South China University of Technology, Guangzhou 510641, China.|College of Life Science, Northwest A&F University, Yangling, Shannxi 712100, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: FeiLong
authors.affiliation: First Clinical Medical College, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
authors.forename: Li
authors.initials: L
authors.lastname: ZhiHong
authors.affiliation: Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Xian
authors.affiliation: Beijing University of Chinese Medicine, Beijing 100029, China.|Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
authors.forename: Shang
authors.initials: S
authors.lastname: HongCai
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000302:isolation & purification; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000737:chemistry*; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D009682:Magnetic Resonance Spectroscopy; D055432:Metabolomics; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D004365:Drugs, Chinese Herbal; C528580:qishen yiqi